Lysosomal membrane stability plays a major role in the cytotoxic activity of the anti-proliferative agent, di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT)

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1863, Issue 7, 2016, Pages 1665-1681

  Gutierrez, Elaine M ^a   Seebacher, Nicole A ^a   Arzuman, Laila ^a   Kovacevic, Zaklina ^a   Lane, Darius J R ^a   Richardson, Vera ^a   Merlot, Angelica M ^a   Lok, Hiu ^a   Kalinowski, Danuta S ^a   Sahni, Sumit ^a   Jansson, Patric J ^a   Richardson, Des R ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Autophagy; Dp44mT; Lysosomal membrane permeabilization; Lysosomes

Indexed keywords

3BETA (2 DIETHYLAMINOETHOXY)ANDROST 5 EN 17 ONE; ANTINEOPLASTIC AGENT; DI 2 PYRIDYLKETONE 4,4 DIMETHYL 3 THIOSEMICARBAZONE; HEAT SHOCK PROTEIN 70; METHYL BETA CYCLODEXTRIN; THIOSEMICARBAZONE DERIVATIVE; UNCLASSIFIED DRUG; 3-BETA-(2-(DIETHYLAMINO)ETHOXY)ANDROST-5-EN-17-ONE; ANDROSTANE DERIVATIVE; BETA CYCLODEXTRIN DERIVATIVE; CHOLESTEROL; DI-2-PYRIDYLKETONE-4,4-DIMETHYL-3-THIOSEMICARBAZONE; HYPOCHOLESTEROLEMIC AGENT; METHYL-BETA-CYCLODEXTRIN;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; AUTOPHAGOSOME; AUTOPHAGY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; LYSOSOME MEMBRANE; MEMBRANE STABILIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; BREAST NEOPLASMS; DOSE RESPONSE; DRUG EFFECTS; FEMALE; GENETIC TRANSFECTION; GENETICS; IC50; INTRACELLULAR MEMBRANE; LYSOSOME; MCF 7 CELL LINE; METABOLISM; PATHOLOGY; PERMEABILITY; RNA INTERFERENCE;

ANDROSTENES; ANTICHOLESTEREMIC AGENTS; ANTINEOPLASTIC AGENTS; AUTOPHAGY; BETA-CYCLODEXTRINS; BREAST NEOPLASMS; CELL PROLIFERATION; CHOLESTEROL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HSP70 HEAT-SHOCK PROTEINS; HUMANS; INHIBITORY CONCENTRATION 50; INTRACELLULAR MEMBRANES; LYSOSOMES; MCF-7 CELLS; PERMEABILITY; RNA INTERFERENCE; THIOSEMICARBAZONES; TRANSFECTION;

EID: 84964822103     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2016.04.017     Document Type: Article

References (79)

1. Boya P. Lysosomal function and dysfunction: mechanism and disease. Antioxid. Redox Signal. 2012, 17:766-774.
2. Terman A., Kurz T. Lysosomal iron, iron chelation, and cell death. Antioxid. Redox Signal. 2013, 18:888-898.
3. Kallunki T., Olsen O.D., Jaattela M. Cancer-associated lysosomal changes: friends or foes?. Oncogene 2013, 32:1995-2004.
4. Kreuzaler P., Watson C.J. Killing a cancer: what are the alternatives?. Nat. Rev. Cancer 2012, 12:411-424.
5. Jansson P.J., Yamagishi T., Arvind A., Seebacher N., Gutierrez E., Stacy A., Maleki S., Sharp D., Sahni S., Richardson D.R. Di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT) overcomes multidrug resistance by a novel mechanism involving the hijacking of lysosomal P-glycoprotein (Pgp). J. Biol. Chem. 2015, 290:9588-9603.
6. Lovejoy D.B., Jansson P.J., Brunk U.T., Wong J., Ponka P., Richardson D.R. Antitumor activity of metal-chelating compound Dp44mT is mediated by formation of a redox-active copper complex that accumulates in lysosomes. Cancer Res. 2011, 71:5871-5880.
7. Gutierrez E., Richardson D.R., Jansson P.J. The anticancer agent di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT) overcomes prosurvival autophagy by two mechanisms: persistent induction of autophagosome synthesis and impairment of lysosomal integrity. J. Biol. Chem. 2014, 289:33568-33589.
8. Gyrd-Hansen M., Nylandsted J., Jaattela M. Heat shock protein 70 promotes cancer cell viability by safeguarding lysosomal integrity. Cell Cycle 2004, 3:1484-1485.
9. Guicciardi M.E., Leist M., Gores G.J. Lysosomes in cell death. Oncogene 2004, 23:2881-2890.
10. Cirman T., Oresic K., Mazovec G.D., Turk V., Reed J.C., Myers R.M., Salvesen G.S., Turk B. Selective disruption of lysosomes in HeLa cells triggers apoptosis mediated by cleavage of Bid by multiple papain-like lysosomal cathepsins. J. Biol. Chem. 2004, 279:3578-3587.
11. 2 is a consequence of lysosomal rupture. Biochem. J. 2001, 356:549-555.
12. Boya P., Andreau K., Poncet D., Zamzami N., Perfettini J.L., Metivier D., Ojcius D.M., Jaattela M., Kroemer G. Lysosomal membrane permeabilization induces cell death in a mitochondrion-dependent fashion. J. Exp. Med. 2003, 197:1323-1334.
13. Nylandsted J., Gyrd-Hansen M., Danielewicz A., Fehrenbacher N., Lademann U., Hoyer-Hansen M., Weber E., Multhoff G., Rohde M., Jaattela M. Heat shock protein 70 promotes cell survival by inhibiting lysosomal membrane permeabilization. J. Exp. Med. 2004, 200:425-435.
14. Kirkegaard T., Jaattela M. Lysosomal involvement in cell death and cancer. Biochim. Biophys. Acta 2009, 1793:746-754.
15. Yuan J., Lovejoy D.B., Richardson D.R. Novel di-2-pyridyl derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment. Blood 2004, 104:1450-1458.
16. Whitnall M., Howard J., Ponka P., Richardson D.R. A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:14901-14906.
17. Rao V.A., Klein S.R., Agama K.K., Toyoda E., Adachi N., Pommier Y., Shacter E.B. The iron chelator Dp44mT causes DNA damage and selective inhibition of topoisomerase IIalpha in breast cancer cells. Cancer Res. 2009, 69:948-957.
18. Kovacevic Z., Chikhani S., Lovejoy D.B., Richardson D.R. Novel thiosemicarbazone iron chelators induce up-regulation and phosphorylation of the metastasis suppressor N-myc down-stream regulated gene 1: a new strategy for the treatment of pancreatic cancer. Mol. Pharmacol. 2011, 80:598-609.
19. Lovejoy D.B., Sharp D.M., Seebacher N., Obeidy P., Prichard T., Stefani C., Basha M.T., Sharpe P.C., Jansson P.J., Kalinowski D.S., Bernhardt P.V., Richardson D.R. Novel second-generation di-2-pyridylketone thiosemicarbazones show synergism with standard chemotherapeutics and demonstrate potent activity against lung cancer xenografts after oral and intravenous administration in vivo. J. Med. Chem. 2012, 55:7230-7244.
20. Chen Z., Zhang D., Yue F., Zheng M., Kovacevic Z., Richardson D.R. The iron chelators Dp44mT and DFO inhibit TGFbeta-induced epithelial-mesenchymal transition via up-regulation of N-myc downstream-regulated gene 1 (NDRG1). J. Biol. Chem. 2012, 287:17016-17028.
21. Liu W., Xing F., Iiizumi-Gairani M., Okuda H., Watabe M., Pai S.K., Pandey P.R., Hirota S., Kobayashi A., Mo Y.-Y., Fukuda K., Li Y., Watabe K. N-myc downstream regulated gene 1 modulates Wnt-β-catenin signalling and pleiotropically suppresses metastasis. EMBO Mol. Med 2012, 4:93-108.
22. Wang J., Yin D., Xie C., Zheng T., Liang Y., Hong X., Lu Z., Song X., Song R., Yang H., Sun B., Bhatta N., Meng X., Pan S., Jiang H., Liu L. The iron chelator Dp44mT inhibits hepatocellular carcinoma metastasis via N-Myc downstream-regulated gene 2 (NDRG2)/gp130/STAT3 pathway. Oncotarget 2014, 5:8478-8491.
23. Lui G.Y., Kovacevic Z., Richardson V., Merlot A.M., Kalinowski D.S., Richardson D.R. Targeting cancer by binding iron: dissecting cellular signaling pathways. Oncotarget 2015, 6:18748-18779.
24. Yu Y., Suryo Rahmanto Y., Richardson D.R. Bp44mT: an orally active iron chelator of the thiosemicarbazone class with potent anti-tumour efficacy. Br. J. Pharmacol. 2012, 165:148-166.
25. Merlot A.M., Kalinowski D.S., Richardson D.R. Novel chelators for cancer treatment: where are we now?. Antioxid. Redox Signal. 2013, 18:973-1006.
26. Jansson P.J., Kalinowski D.S., Lane D.J., Kovacevic Z., Seebacher N.A., Fouani L., Sahni S., Merlot A.M., Richardson D.R. The renaissance of polypharmacology in the development of anti-cancer therapeutics: inhibition of the "triad of death" in cancer by di-2-pyridylketone thiosemicarbazones. Pharmacol. Res. 2015, 100:255-260.
27. Richardson D.R., Sharpe P.C., Lovejoy D.B., Senaratne D., Kalinowski D.S., Islam M., Bernhardt P.V. Dipyridyl thiosemicarbazone chelators with potent and selective antitumor activity form iron complexes with redox activity. J. Med. Chem. 2006, 49:6510-6521.
28. Kalinowski D.S., Richardson D.R. The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol. Rev. 2005, 57:547-583.
29. Spasojevic I., Armstrong S.K., Brickman T.J., Crumbliss A.L. Electrochemical behavior of the Fe(III) complexes of the cyclic hydroxamate siderophores alcaligin and desferrioxamine E. Inorg. Chem. 1999, 38:449-454.
30. Chaston T.B., Lovejoy D.B., Watts R.N., Richardson D.R. Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311. Clin. Cancer Res. 2003, 9:402-414.
31. Turk B., Turk V. Lysosomes as "suicide bags" in cell death: myth or reality?. J. Biol. Chem. 2009, 284:21783-21787.
32. Johansson A.C., Appelqvist H., Nilsson C., Kagedal K., Roberg K., Ollinger K. Regulation of apoptosis-associated lysosomal membrane permeabilization. Apoptosis 2010, 15:527-540.
33. Kurz T., Terman A., Gustafsson B., Brunk U. Lysosomes in iron metabolism, ageing and apoptosis. Histochem. Cell Biol. 2008, 129:389-406.
34. Cesen M.H., Pegan K., Spes A., Turk B. Lysosomal pathways to cell death and their therapeutic applications. Exp. Cell Res. 2012, 318:1245-1251.
35. Deng D., Jiang N., Hao S.J., Sun H., Zhang G.J. Loss of membrane cholesterol influences lysosomal permeability to potassium ions and protons. Biochim. Biophys. Acta 2009, 1788:470-476.
36. Jadot M., Andrianaivo F., Dubois F., Wattiaux R. Effects of methylcyclodextrin on lysosomes. Eur. J. Biochem. 2001, 268:1392-1399.
37. Doulias P.-T., Christoforidis S., Brunk U.T., Galaris D. Endosomal and lysosomal effects of desferrioxamine: protection of HeLa cells from hydrogen peroxide-induced DNA damage and induction of cell-cycle arrest. Free Radic. Biol. Med. 2003, 35:719-728.
38. Kurz T., Brunk U.T. Autophagy of HSP70 and chelation of lysosomal iron in a non-redox-active form. Autophagy 2009, 5:93-95.
39. Uphoff C.C., Drexler H.G. Comparative PCR analysis for detection of mycoplasma infections in continuous cell lines. In Vitro Cell. Dev. Biol. Anim. 2002, 38:79-85.
40. Gao J., Richardson D.R. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents, IV: the mechanisms involved in inhibiting cell-cycle progression. Blood 2001, 98:842-850.
41. Richardson D., Tran E., Ponka P. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. Blood 1995, 86:4295-4306.
42. Esteve J.M., Knecht E. Mechanisms of autophagy and apoptosis: recent developments in breast cancer cells. World J. Biol. Chem. 2011, 2:232-238.
43. Merlot A.M., Pantarat N., Menezes S.V., Sahni S., Richardson D.R., Kalinowski D.S. Cellular uptake of the antitumor agent Dp44mT occurs via a carrier/receptor-mediated mechanism. Mol. Pharmacol. 2013, 84:911-924.
44. Lane D.J., Saletta F., Suryo Rahmanto Y., Kovacevic Z., Richardson D.R. N-myc downstream regulated 1 (NDRG1) is regulated by eukaryotic initiation factor 3a (eIF3a) during cellular stress caused by iron depletion. PLoS One 2013, 8.
45. Guo F., Rocha K., Bali P., Pranpat M., Fiskus W., Boyapalle S., Kumaraswamy S., Balasis M., Greedy B., Armitage E.S.M., Lawrence N., Bhalla K. Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin. Cancer Res. 2005, 65:10536-10544.
46. McLean P.J., Klucken J., Shin Y., Hyman B.T. Geldanamycin induces Hsp70 and prevents alpha-synuclein aggregation and toxicity in vitro. Biochem. Biophys. Res. Commun. 2004, 321:665-669.
47. Yu Y., Szczepek A., Haupt H., Mazurek B. Geldanamycin induces production of heat shock protein 70 and partially attenuates ototoxicity caused by gentamicin in the organ of Corti explants. J. Biomed. Sci. 2009, 16:1-12.
48. Bivik C., Rosdahl I., Ollinger K. Hsp70 protects against UVB induced apoptosis by preventing release of cathepsins and cytochrome c in human melanocytes. Carcinogenesis 2007, 28:537-544.
49. Paglin S., Hollister T., Delohery T., Hackett N., McMahill M., Sphicas E., Domingo D., Yahalom J. A novel response of cancer cells to radiation involves autophagy and formation of acidic vesicles. Cancer Res. 2001, 61:439-444.
50. Yan L.-J., Christians E.S., Liu L., Xiao X., Sohal R.S., Benjamin I.J. Mouse heat shock transcription factor 1 deficiency alters cardiac redox homeostasis and increases mitochondrial oxidative damage. EMBO J. 2002, 21:5164-5172.
51. Appelqvist H., Sandin L., Bjornstrom K., Saftig P., Garner B., Ollinger K., Kagedal K. Sensitivity to lysosome-dependent cell death is directly regulated by lysosomal cholesterol content. PLoS One 2012, 7.
52. Cenedella R.J. Cholesterol synthesis inhibitor U18666A and the role of sterol metabolism and trafficking in numerous pathophysiological processes. Lipids 2009, 44:477-487.
53. Murai T., Sato C., Sato M., Nishiyama H., Suga M., Mio K., Kawashima H. Membrane cholesterol modulates the hyaluronan-binding ability of CD44 in T lymphocytes and controls rolling under shear flow. J. Cell Sci. 2013, 126:3284-3294.
54. Sobo K., Le Blanc I., Luyet P.-P., Fivaz M., Ferguson C., Parton R.G., Gruenberg J., van der Goot F.G. Late endosomal cholesterol accumulation leads to impaired intra-endosomal trafficking. PLoS One 2007, 2.
55. Huynh K.K., Gershenzon E., Grinstein S. Cholesterol accumulation by macrophages impairs phagosome maturation. J. Biol. Chem. 2008, 283:35745-35755.
56. Eskelinen E.-L. Roles of LAMP-1 and LAMP-2 in lysosome biogenesis and autophagy. Mol. Asp. Med. 2006, 27:495-502.
57. Kroemer G., Jaattela M. Lysosomes and autophagy in cell death control. Nat. Rev. Cancer 2005, 5:886-897.
58. Mizushima N., Yoshimori T., Levine B. Methods in mammalian autophagy research. Cell 2010, 140:313-326.
59. Sahni S., Bae D.H., Lane D.J., Kovacevic Z., Kalinowski D.S., Jansson P.J., Richardson D.R. The metastasis suppressor, N-myc downstream-regulated gene 1 (NDRG1), inhibits stress-induced autophagy in cancer cells. J. Biol. Chem. 2014, 289:9692-9709.
60. Klionsky D.J., Abdelmohsen K., Abe A., Abedin M.J., Abeliovich H., Acevedo Arozena A., Adachi H., Adams C.M., Adams P.D., Adeli K., et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy 2016, 12:1-222.
61. Bjorkoy G., Lamark T., Brech A., Outzen H., Perander M., Overvatn A., Stenmark H., Johansen T. p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death. J. Cell Biol. 2005, 171:603-614.
62. Puissant A., Robert G., Fenouille N., Luciano F., Cassuto J.-P., Raynaud S., Auberger P. Resveratrol promotes autophagic cell death in chronic myelogenous leukemia cells via JNK-mediated p62/SQSTM1 expression and AMPK activation. Cancer Res. 2010, 70:1042-1052.
63. Robert G., Ben Sahra I., Puissant A., Colosetti P., Belhacene N., Gounon P., Hofman P., Bost F., Cassuto J.-P., Auberger P. Acadesine kills chronic myelogenous leukemia (CML) cells through PKC-dependent induction of autophagic cell death. PLoS One 2009, 4.
64. Potuckova E., Roh J., Machacek M., Sahni S., Stariat J., Sestak V., Jansova H., Haskova P., Jirkovska A., Vavrova K., Kovarikova P., Kalinowski D.S., Richardson D.R., Simunek T. In vitro characterization of the pharmacological properties of the anti-cancer chelator, Bp4eT, and its phase I metabolites. PLoS One 2015, 10.
65. Yang Z.J., Chee C.E., Huang S., Sinicrope F.A. The role of autophagy in cancer: therapeutic implications. Mol. Cancer Ther. 2011, 10:1533-1541.
66. Yamamoto A., Tagawa Y., Yoshimori T., Moriyama Y., Masaki R., Tashiro Y. Bafilomycin A1 prevents maturation of autophagic vacuoles by inhibiting fusion between autophagosomes and lysosomes in rat hepatoma cell line, H-4-II-E cells. Cell Struct. Funct. 1998, 23:33-42.
67. Bolte S., Cordelieres F.P. A guided tour into subcellular colocalization analysis in light microscopy. J. Microsc. 2006, 224:213-232.
68. Manders E.M.M., Verbeek F.J., Aten J.A. Measurement of co-localization of objects in dual-colour confocal images. J. Microsc. 1993, 169:375-382.
69. Appelqvist H., Waster P., Kagedal K., Ollinger K. The lysosome: from waste bag to potential therapeutic target. J. Mol. Cell Biol. 2013, 5:214-226.
70. Pryor P.R., Luzio J.P. Delivery of endocytosed membrane proteins to the lysosome. Biochim. Biophys. Acta 2009, 1793:615-624.
71. Saftig P., Klumperman J. Lysosome biogenesis and lysosomal membrane proteins: trafficking meets function. Nat. Rev. Mol. Cell Biol. 2009, 10:623-635.
72. Kagedal K., Johansson U., Ollinger K. The lysosomal protease cathepsin D mediates apoptosis induced by oxidative stress. FASEB J. 2001, 15:1592-1594.
73. Polla B.S., Kantengwa S., Francois D., Salvioli S., Franceschi C., Marsac C., Cossarizza A. Mitochondria are selective targets for the protective effects of heat shock against oxidative injury. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:6458-6463.
74. Fehrenbach E., Northoff H. Free radicals, exercise, apoptosis, and heat shock proteins. Exerc. Immunol. Rev. 2001, 7:66-89.
75. Fouchier F., Mego J.L., Dang J., Simon C. Thyroid lysosomes: the stability of the lysosomal membrane. Eur. J. Cell Biol. 1983, 30:272-278.
76. Reiners J.J., Kleinman M., Kessel D., Mathieu P.A., Caruso J.A. Nonesterified cholesterol content of lysosomes modulates susceptibility to oxidant-induced permeabilization. Free Radic. Biol. Med. 2011, 50:281-294.
77. Ko D.C., Milenkovic L., Beier S.M., Manuel H., Buchanan J., Scott M.P. Cell-autonomous death of cerebellar purkinje neurons with autophagy in Niemann-Pick type C disease. PLoS Genet. 2005, 1:81-95.
78. Pacheco C.D., Kunkel R., Lieberman A.P. Autophagy in Niemann-Pick C disease is dependent upon Beclin-1 and responsive to lipid trafficking defects. Hum. Mol. Genet. 2007, 16:1495-1503.
79. Elrick M.J., Yu T., Chung C., Lieberman A.P. Impaired proteolysis underlies autophagic dysfunction in Niemann-Pick type C disease. Hum. Mol. Genet. 2012, 21:4876-4887.